Humana (HUM) has begun full operations at a new $83 million CenterWell Pharmacy mail order distribution center in Orlando, Florida, expanding prescription delivery capacity for members across the state and nationwide.

The new Orlando CenterWell Pharmacy facility comes as Humana’s stock has picked up strong momentum, with a 30 day share price return of 37.65% and a 90 day share price return of 81.21%, even though the 3 year total shareholder return has declined 32.73%.

If this kind of healthcare expansion has your attention, it could be a good moment to see what else is emerging in the sector through our 39 healthcare AI stocks

With Humana shares up 37.65% over 30 days and 81.21% over 90 days, yet the 3-year total return still down 32.73%, is this sharp rebound pointing to value on the table, or is the market already pricing in future growth?

Most Popular Narrative: 53.9% Overvalued

Compared with Humana’s last close at $327.54, the most followed narrative on the stock places fair value at $212.87. This implies a steep valuation gap that is hard to ignore.

Humana (NYSE: HUM) is navigating a regulatory environment that is becoming increasingly unforgiving. While Medicare Advantage has been a powerful growth engine for insurers over the past decade, recent developments suggest that oversight is intensifying and the margin for error is shrinking.

It may be worth asking why a business with sizeable Medicare Advantage exposure, tighter oversight, and slim margins is still priced well above this fair value line. The narrative leans on a specific earnings trajectory and profitability profile that has to do a lot of heavy lifting. If you want to see exactly which assumptions are doing that work, the full story is worth a closer look.

Result: Fair Value of $212.87 (OVERVALUED)

However, the picture can change quickly if regulatory scrutiny eases or if Humana’s Medicare documentation controls and margins prove more resilient than expected.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Cash Flows Tell a Different Story

While the most popular community narrative sees Humana as 53.9% overvalued at a fair value of $212.87, the Simply Wall St DCF model points in the opposite direction, with an estimated future cash flow value of $981.54 per share, well above the current $327.54 price.

When one approach suggests a stretched price and another suggests a wide gap to intrinsic value, it raises a simple question for you: which set of assumptions feels more realistic?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Humana for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between risk and reward, this is a moment to look at the numbers yourself and decide quickly where you stand based on the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Humana has sharpened your focus, do not stop here. Broaden your watchlist now so you are not relying on a single stock story.

• Zero in on potential value opportunities by scanning our 47 high quality undervalued stocks that combine quality fundamentals with pricing that may still leave room on the table.
• Strengthen your income stream by reviewing the 10 dividend fortresses and see which companies pair higher yields with robust underlying businesses.
• Dial down risk in your portfolio by checking the 63 resilient stocks with low risk scores so you are not caught off guard when conditions change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.